今日药学

2020, v.30(04) 235-238

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

PD-1/PD-L1抑制剂治疗新型冠状病毒肺炎可行性探讨
Study on the Feasibility of PD-1/PD-L1 Inhibitor in the Treatment of Coronavirus Disease 2019

孔艺;吴红卫;陈永;赖莎;杨泽民;李雄;陈吉生;
KONG Yi;WU Hongwei;CHEN Yong;LAI Sha;YANG Zemin;LI Xiong;CHEN Jisheng;Department of Pharmacy,The First Affiliated Hospital of Guangdong Pharmaceutical University;School of clinical pharmacy,Guangdong Pharmaceutical University;

摘要(Abstract):

2019年12月底我国湖北省武汉市出现由新型冠状病毒引起的新型冠状病毒肺炎,目前临床尚无针对性的特效药或疫苗。本文从PD-1/PD-L1的结构、功能、PD-1/PD-L1抑制剂与免疫相关性肺炎及新型冠状病毒肺炎的临床表现和实验室检查等方面进行综述,认为PD-1/PD-L1抑制剂应用于新型冠状病毒肺炎的治疗需谨慎。
In late December 2019,a cluster of unexplained pneumonia cases has been reported in Wuhan,China. This article reviewed the structure, functions of PD-1/PD-L1, immuno-associated pneumonia of PD-1/PD-L1 inhibitors, and the clinical manifestations of COVID-19. Current evidence suggested that PD-1/PD-L1 inhibitors in the treatment of COVID-19 should be cautious.

关键词(KeyWords): PD-1/PD-L1;抑制剂;新型冠状病毒;新型冠状病毒肺炎
PD-1/PD-L1;Inhibitor;2019-nCoV;COVID-19

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 孔艺;吴红卫;陈永;赖莎;杨泽民;李雄;陈吉生;
KONG Yi;WU Hongwei;CHEN Yong;LAI Sha;YANG Zemin;LI Xiong;CHEN Jisheng;Department of Pharmacy,The First Affiliated Hospital of Guangdong Pharmaceutical University;School of clinical pharmacy,Guangdong Pharmaceutical University;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享